iBio logo
iBio IBIO
$ 1.19 1.24%
report update icon

Quarterly report 2026-Q4
added 08-28-2026

iBio EPS Ratio | IBIO

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio iBio

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
-0.32 -1.75 -6.5 -106 -5.78 -3 -0.61 -0.94 -1.54 -1.64 -0.12 -0.09 -0.06 -0.13 -0.14 -0.39 -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-0.06 -106 -8.07

Quarterly EPS Ratio iBio

2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- -0.06 -0.09 -0.11 -0.09 -0.11 - -0.49 -0.48 -0.46 - -0.85 -4.42 -4.8 - -11.1 -68.4 -2.05 -5.54 -1.42 -1.37 -1.03 -2.4 -0.04 -0.04 -0.05 -0.04 -0.05 -0.69 -0.21 -0.69 -0.21 -0.24 -0.25 -0.24 -0.25 -0.41 -0.42 -0.04 -0.04 -0.04 -0.03 -0.04 -0.03 -0.03 -0.02 -0.03 -0.02 -0.02 -0.02 -0.02 -0.02 -0.03 0.01 -0.03 0.01 -0.02 -0.04 -0.02 -0.04 -0.05 0.01 -0.05 0.01

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
0.01 -68.4 -1.83

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
1.02 $ 263.04 0.49 % $ 465 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
-0.49 $ 11.41 2.15 % $ 3.41 B canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
-0.53 $ 5.53 6.02 % $ 678 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
-1.12 $ 1.09 3.74 % $ 139 M schweizSchweiz
Amryt Pharma plc Amryt Pharma plc
AMYT
-0.66 - - $ 621 M britainBritain
Evelo Biosciences Evelo Biosciences
EVLO
-1.31 - -14.46 % $ 27.9 M usaUSA
Allakos Allakos
ALLK
-1.3 - - $ 28.6 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-2.84 - - $ 231 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
-0.5 - -7.23 % $ 13 M usaUSA
Chimerix Chimerix
CMRX
-0.99 - - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
-2.33 - - $ 401 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
0.62 $ 8.61 0.16 % $ 2.05 B usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
-50.8 - -9.21 % $ 2.55 M usaUSA
89bio 89bio
ETNB
-3.51 - - $ 1.55 B usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
-1.5 - - $ 384 M britainBritain
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
-1.45 - - $ 1.41 B canadaCanada
Guardion Health Sciences Guardion Health Sciences
GHSI
0.12 - -0.31 % $ 3.64 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
-0.48 - -15.0 % $ 3.04 M usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
-1.2 - 0.42 % $ 213 M usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
-0.93 - - $ 370 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
-2.04 - - $ 763 M usaUSA
Humanigen Humanigen
HGEN
-0.79 - -81.12 % $ 4.28 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
-3.47 - -6.92 % $ 79.4 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
-0.5 - - $ 643 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
-3.24 - - $ 76.9 M usaUSA
IMV IMV
IMV
-4.55 - - $ 13.1 M canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
-0.16 - - $ 13.6 B usaUSA
Kinnate Biopharma Kinnate Biopharma
KNTE
-2.42 - - $ 123 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
-2.92 - - $ 2.6 B usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
-2.16 - -3.69 % $ 12.4 M usaUSA
Kronos Bio Kronos Bio
KRON
-1.43 - 1.49 % $ 50.8 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
-11.7 - - $ 12.2 B usaUSA
Landos Biopharma Landos Biopharma
LABP
-3.5 - 0.58 % $ 144 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
0.72 - - $ 154 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
-1.24 - - $ 229 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
-4.18 - - $ 35.3 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
-0.08 - - $ 216 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
-0.08 - - $ 23.9 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
-13.2 - - $ 3.3 B usaUSA
NexImmune NexImmune
NEXI
-30.8 - 70.13 % $ 4.12 M usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
-3.38 - -42.97 % $ 1.05 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
-6.83 - -37.48 % $ 476 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
-0.05 - -19.68 % $ 18.4 M canadaCanada
ObsEva SA ObsEva SA
OBSV
-1.67 - -15.52 % $ 10.5 M schweizSchweiz
Oncorus Oncorus
ONCR
-2.99 - -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
-0.87 - 31.87 % $ 1.61 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
-13.4 - -24.12 % $ 1.56 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
0.68 - - $ 109 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
-1.18 - 1.02 % $ 90.8 M britainBritain